For a deeper look at where the wider GLP-1 obesity pipeline is heading, including the emerging role of combination therapies, see our earlier analysis: CagriSema: what the phase 3 data shows.
Patients should never skip this titration process or increase doses more rapidly than recommended, as this significantly increases the risk and severity of gastrointestinal side effects
Reduced efficacy concerns GLP-1 receptor agonists are designed to work at specific doses to achieve optimal receptor activation (saturation) and to provide full therapeutic effect
Along the way, researchers began noticing something unexpected
These symptoms typically emerge during dose escalation and often diminish over several weeks as physiological adaptation occurs
The value of a telehealth platform like FeelGood is that it makes that conversation accessible, affordable, and fast